Foqus MRI Acceleration Software
AI-powered MRI software reducing scan times from 40 to under 10 minutes
Company profile
Company profile
Foqus Technologies Inc. is a Toronto-based medical technology company redefining what's possible in magnetic resonance imaging (MRI) through advanced software innovation. The company has developed FDA-cleared technology that leverages proprietary artificial intelligence and quantum-enabled algorithms to dramatically reduce MRI scan times from around 40 minutes to under 10 minutes. By accelerating imaging without requiring costly hardware upgrades, Foqus empowers healthcare providers to increase scanner throughput, reduce patient wait times, and improve access to high-quality diagnostic care. This breakthrough represents a major leap forward for MRI efficiency and accessibility, offering a scalable, cost-effective solution that aligns with the future of value-based healthcare. The company's software-based approach allows existing MRI infrastructure to operate more efficiently, addressing critical bottlenecks in diagnostic imaging. Foqus joined Medical Innovation Xchange (MIX) in March 2026 to access experienced mentors, training programs, and a community of experts with real-world experience in building, validating, and commercializing regulated medical technologies. As the company advances toward broader deployment, it is focused on refining go-to-market strategies, expanding its network, and strengthening partnerships that support scalable clinical adoption to bring their technology to more providers and patients across healthcare systems.
Company description Foqus Technologies official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
No clinical focus areas are currently listed.
Other deployment with recorded integration context.
Company milestones
Joined Medical Innovation Xchange (MIX) as affiliate company in March 2026, focusing on go-to-market strategy refinement and commercialization pathways
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
AI-powered MRI software reducing scan times from 40 to under 10 minutes
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
No linked records are currently available.
Clinical validation
No linked records are currently available.
Regulatory
K241982 · 510k · Apr 4, 2025
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
MRI imaging acceleration
Healthcare provider operational efficiency
Improved patient access to diagnostic care
05 · Leadership
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Recent articles published on Foqus Technologies's official website.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.